Gyre Therapeutics (NASDAQ:GYRE) Trading Up 9% – Still a Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price shot up 9% during trading on Thursday . The company traded as high as $7.13 and last traded at $7.1050. Approximately 47,569 shares changed hands during mid-day trading, a decline of 50% from the average session volume of 95,853 shares. The stock had previously closed at $6.52.

Wall Street Analyst Weigh In

GYRE has been the subject of several recent analyst reports. Zacks Research lowered shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Weiss Ratings lowered Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Gyre Therapeutics has an average rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Stock Performance

The stock has a market cap of $818.34 million, a price-to-earnings ratio of -81.55 and a beta of 1.89. The firm’s 50-day simple moving average is $6.54 and its two-hundred day simple moving average is $7.26.

Insider Buying and Selling

In related news, CEO Ying Luo sold 10,136 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total value of $81,493.44. Following the completion of the sale, the chief executive officer owned 2,565,226 shares of the company’s stock, valued at $20,624,417.04. This trade represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Weiguo Ye sold 12,820 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $6.15, for a total value of $78,843.00. Following the transaction, the chief operating officer directly owned 700,000 shares in the company, valued at approximately $4,305,000. This represents a 1.80% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 32,535 shares of company stock valued at $219,580. 9.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Gyre Therapeutics

Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its position in Gyre Therapeutics by 131.8% in the first quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after purchasing an additional 14,365 shares during the period. Bank of New York Mellon Corp lifted its position in Gyre Therapeutics by 4.7% during the 1st quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock valued at $301,000 after purchasing an additional 1,941 shares during the period. Barclays PLC boosted its stake in shares of Gyre Therapeutics by 38.3% in the 4th quarter. Barclays PLC now owns 18,531 shares of the company’s stock valued at $131,000 after purchasing an additional 5,135 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Gyre Therapeutics by 37.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after buying an additional 45,772 shares during the period. Finally, State Street Corp grew its position in shares of Gyre Therapeutics by 10.7% during the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after buying an additional 19,472 shares during the period. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.